Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs

He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, Gu J, Zhang Y, Li W, Li M, et al. · Frontiers in Pharmacology

Elimination half-life of intact BPC157 under 30 minutes with linear kinetics at every dose; absolute bioavailability after intramuscular injection was roughly 14–19% in rats and 45–51% in dogs; excretion was urinary and biliary, and the peptide broke down rapidly into small fragments and free amino acids.

Population

Sprague-Dawley rats and beagle dogs, single IV, single and repeated IM dosing

Intervention

Synthetic BPC157, including tritium-labelled tracer

Comparator

Cross-species and cross-route comparison

Limitations

The first formal ADME work in two species, and independent of the originating network — but no human pharmacokinetic study of comparable design exists, and the sub-30-minute half-life is hard to reconcile with the multi-day effects reported in the healing models.